PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Research Center for Neurosurgery and Functional Nerves, Shahid Beheshti University of Medical Sciences, Tehran, Iran.\', \'Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: tabarsi@nritld.ac.ir.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1567-5769(20)33796-610.1016/j.intimp.2020.107329
?:hasPublicationType
?:journal
  • International immunopharmacology
is ?:pmid of
?:pmid
?:pmid
  • 33412395
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.051
?:rankingScore_hIndex
  • 94
?:title
  • Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all